<DOC>
	<DOC>NCT02156895</DOC>
	<brief_summary>The objective of this study is to monitor the usage of INLYTA® in real practice, including the adverse events associated with INLYTA®.</brief_summary>
	<brief_title>Post Marketing Surveillance Study to Observe Safety and Efficacy of Inlyta in South Korea</brief_title>
	<detailed_description>Investigators can choose any patient who is within the scope of I/E criteria</detailed_description>
	<mesh_term>Carcinoma, Renal Cell</mesh_term>
	<mesh_term>Axitinib</mesh_term>
	<criteria>Patients diagnosed as advanced RCC after failure of one prior systemic therapy. Any patient who does not agree that Pfizer or companies working on behalf of Pfizer can use his/her information. Patients with hypersensitivity to axitinib or to any other component of INLYTA® . Patients under 18. Pregnant women.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2017</verification_date>
	<keyword>Korean PMS of Axitinib</keyword>
	<keyword>Metastatic RCC ; 2nd line only</keyword>
</DOC>